Rhythm Pharmaceuticals, Inc. (RYTM)
Develops drugs to treat rare genetic forms of obesity and related disorders.
$106.86+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+21.0%
The outlook
RYTM is trading above both its 50- and 200-day moving averages, sitting roughly two-thirds of the way up its 52-week range. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and the average price target sits about 29% above the current level. The data reflects a bullish technical setup paired with positive analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 14 analysts
Price trendAbove its 50- & 200-day averages
52-week range68% of the way from its 52-week low to high
Price targetAvg target +29% vs current price
Analyst price target
~12-month · 14 analysts$138.36average target+29.5% vs now
Now $106.86
Low $105.00High $155.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$7.33B
52-wk high
$122.20
52-wk low
$74.50
50-day avg
$98.74
200-day avg
$98.94
Trailing P/E
—